Efficacy and safety of human recombinant endostatin plus pemetrexed and cisplatin in the treatment of advanced non-small cell lung cancer

VernacularTitle:重组人血管内皮抑制素联合培美曲塞和顺铂治疗晚期非小细胞肺癌的临床观察
Author: Yanzhi PENG ; Guodong ZHANG
Publication Type:Journal Article
Keywords: Carcinoma,non-small cell lung; Drug therapy,combination
From: Chinese Journal of General Practitioners 2013;12(4):298-299
CountryChina
Language:Chinese
Abstract: To explore the efficacy and safety of human recombinant endostatin (rh-endostatin) plus pemetrexed and cisplatin in the treatment of advanced non-small cell lung cancer (NSCLC).A total of 79 patients with advanced NSCLC were randomly divided into control group (n =39,pemetrexed plus cisplatin) and study group (n =40,rh-endostatin plus pemetrexed and cisplatin).The short-term relative risks of the test group (19/40,47.5％) was significantly higher than that in the control group (10/39,25.6％).And the clinical benefit rate the test group (33/40,82.5％) was higher than that of the control group (23/39,59.0％,P ＜ 0.05).The predominant adverse effects were bone marrow suppression and digestive reactions.And the incidence rate was not significantly different between two groups.